peptide t

Peptide T, an octapeptide from the V2 region of HIV-1 gp120, is a synthetic octapeptide that potentially acts through competitive inhibition of gp120 binding to the CD4 receptor, as well as binding to vasointestinal peptide receptors and inhibiting cytokine action.

Peptide T acetate is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action

HIV Peptide T (Peptide T), this synthetic octapeptide is an antiviral drug in the treatment of HIV infection. It mainly competitively inhibits the interaction between gp120 (HIV surface protein) and the CD4 receptor, while also interacting with the vascular intestinal The peptide (vasointestinal peptide, VIP) receptor binds homologously and blocks the production and action of cytokines to exert its effect.

Peptide T (TFA), an octapeptide derived from the V2 region of HIV-1 gp120, functions as a ligand for the CD4 receptor, thereby effectively inhibiting HIV binding to the CD4 receptor.

Peptide T amide is an octapeptide segment of HIV envelope gp120 and is used in AIDS therapy.

Highly neurotoxic cell-permeable analog of PHF6. Induces aggregation of Tau peptides.

This peptide, a nuclear localization signal DNA tagged to this peptide efficiently translocates into the cell nucleus.

SV40 T-Ag-derived NLS peptide acetate (SV40 T-Ag-derived NLS peptide acetate) is a nuclear localization signal peptide. The DNA labeled with this peptide can be effectively transferred to the nucleus.

EGF-R (661-681) T669 Peptide, a substrate of MAPK, facilitates the measurement of MAPK catalytic activity [1].

T9 peptide (SKTFNTHPQSTP) is a muscle-targeting peptide that tightly binds to C2C12 myoblasts. When combined with oligonucleotides, T9 peptide enhances specificity towards the heart and quadriceps without similarly targeting the kidney, liver, or diaphragm.

T3 Peptide is an active fragment of tumstatin. By binding to integrins αvβ3/αvβ5, it activates the PI3K/Akt/p70S6K signaling pathway, thereby promoting the proliferation and migration of rat cardiac fibroblasts.

T7 Peptide is an endothelial cell-specific inhibitor. It interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, PKB/Akt, and mTOR signaling pathways in endothelial cells, leading to suppressed protein synthesis and the induction of apoptosis.

Autocamtide-2-related inhibitory peptide TFA salt is a highly specific and potent inhibitor of CaMKII with an IC50 of 40 nM.

RNAIII-inhibiting peptide TFA (RNAIII-inhibiting peptide(TFA))(228544-21-6 free base) inhibits S. aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

EGFRvIII peptide, a synthetic peptide mirroring the EGFRvIII fusion junction—a tumor-specific, perpetually active EGFR variant missing amino acids 6-273 of the wild-type—binds to HLA-A*0201-positive T2 cells under MHC class I at 25 µg/ml. It enables antigen presentation in dendritic cells from human peripheral blood mononuclear cells (PBMCs), thus activating CD8+ cytotoxic T lymphocytes and prompting IFN-γ production. Administered at 15 µg/animal with the TLR5 agonist flagellin B, EGFRvIII peptide elevates CD8+ T cell numbers, lowers regulatory T cells (Tregs) in the brain, diminishes tumor volume, and extends survival in a GL261 glioblastoma mouse model.

NY-ESO-1 (157-165) peptide (TFA) is a peptide derived from the NY-ESO-1 protein. This peptide can activate the immune system and is specifically recognized by CD8+ T cells in HLA-A2 positive individuals, thereby initiating an immune response. It is expressed in various tumors and can serve as a target for tumor immunotherapy.

PD-L1 inhibitory peptide TFA is an inhibitory peptide targeting programmed cell death ligand 1 (PD-L1). It binds to PD-L1, lifting immune suppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA shows potential for use in cancer research.

AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.

ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes.

Transdermal Peptide TD-1 HCl is a novel peptide for enhanced transdermal drug delivery that facilitates the penetration of the skin barrier by several drugs and large hydrophilic proteins, such as insulin and human growth hormoneb.

OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

Polymyxin B nonapeptide TFA (catalog number T64687) is a valuable organic compound for life sciences research.

Akt/SKG Substrate Peptide TFA is a synthetic peptide specifically designed as a substrate for Akt/PKB and is not phosphorylated by p70S6K or MAPK1 [1].

HA Peptide TFA is a nine–amino acid synthetic peptide derived from human influenza hemagglutinin (HA) that is widely applied in cell biology and biochemistry research for the isolation, purification, detection, and tracking of target proteins, serving as a versatile epitope tag and experimental reagent in protein expression and interaction studies.